First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
Lists
Only you see this
Abstract
Switching to maintenance using ZKAB001 showed an acceptable safety profile and provided preliminary evidence of clinical activity in localized patients with osteosarcoma.
BibTeX
@inproceedings{zhou2022first,
author = {Yan Zhou and Qingcheng Yang and Yang Dong and Tong Ji and Bing Zhang and Cheng Yang and Shuier Zheng and Lina Tang and Chenliang Zhou and Guowei Qian and Yujing Huang and Wenxi Yu and Hongtao Li and Yonggang Wang and Aina He and Zan Shen and Qiyuan Bao and Yingqi Hua and Hongyu Bai and Jiayi Zhao and Xiaoyi Li and Xiangrong Dai and Jianjun Zhang and Haiyan Hu and Yang Yao},
title = {{First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001}},
booktitle = {Clinical},
year = {2022},
doi = {10.1158/1078-0432.ccr-22-2470},
}Loading related content...